Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Novartis downgraded to Neutral from Buy at Citi » 04:31
01/26/23
01/26
04:31
01/26/23
04:31
NVS

Novartis

$92.81 /

+0.775 (+0.84%)

, NVO

Novo Nordisk

$138.94 /

-1.06 (-0.76%)

, AZN

AstraZeneca

$66.62 /

+0.335 (+0.51%)

, MRK

Merck

$108.60 /

+0.065 (+0.06%)

, RHHBY

Roche

$40.05 /

+0.1 (+0.25%)

Citi analyst Andrew Baum…

Citi analyst Andrew Baum downgraded Novartis (NVS) to Neutral from Buy with a CHF 86 price target. The shares have outperformed all European pharma majors except Novo Nordisk (NVO) and AstraZeneca (AZN) due to the impact of management action in the last six months, aided by some rotation out of Roche (RHHBY), the analyst tells investors in a research note. Citi reduced Novartis earnings estimates to by up to 8% to reflect a more cautious outlook for Leqvio given competitive pressures from Merck's (MRK) oral PCSK-9 MK-0616 in the U.S. commercial and outside the U.S. market. The firm also highlights material ongoing supply constraints hindering Pluvicto's U.S. launch in prostate cancer.

ShowHide Related Items >><<
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

01/18/23 Berenberg
AstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg
01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/12/23 Barclays
CinCor Pharma downgraded to Equal Weight from Overweight at Barclays
01/05/23 BMO Capital
AstraZeneca initiated with an Outperform at BMO Capital
MRK Merck
$108.60 /

+0.065 (+0.06%)

01/04/23 BofA
Merck upgraded to Buy at BofA on consistent revenue upside
01/04/23 BofA
Merck upgraded to Buy from Neutral at BofA
01/03/23 Wells Fargo
Merck price target raised to $125 from $110 at Wells Fargo
01/03/23 Cowen
Merck price target raised to $120 from $108 at Cowen
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

Tuesday
Hot Stocks
Novo Nordisk trading resumes  09:42
01/24/23
01/24
09:42
01/24/23
09:42
NVO

Novo Nordisk

$141.07 /

-0.005 (-0.00%)

 
ShowHide Related Items >><<
NVO Novo Nordisk
$141.07 /

-0.005 (-0.00%)

NVO Novo Nordisk
$141.07 /

-0.005 (-0.00%)

01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
NVO Novo Nordisk
$141.07 /

-0.005 (-0.00%)

NVO Novo Nordisk
$141.07 /

-0.005 (-0.00%)

NVO Novo Nordisk
$141.07 /

-0.005 (-0.00%)

Hot Stocks
Novo Nordisk trading halted, volatility trading pause  09:33
01/24/23
01/24
09:33
01/24/23
09:33
NVO

Novo Nordisk

$141.07 /

-0.035 (-0.02%)

 
ShowHide Related Items >><<
NVO Novo Nordisk
$141.07 /

-0.035 (-0.02%)

NVO Novo Nordisk
$141.07 /

-0.035 (-0.02%)

01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
NVO Novo Nordisk
$141.07 /

-0.035 (-0.02%)

NVO Novo Nordisk
$141.07 /

-0.035 (-0.02%)

NVO Novo Nordisk
$141.07 /

-0.035 (-0.02%)

Over a week ago
Downgrade
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell » 12:43
01/18/23
01/18
12:43
01/18/23
12:43
RHHBY

Roche

$39.91 /

+0.48 (+1.22%)

, NVO

Novo Nordisk

$140.55 /

+1.6 (+1.15%)

As previously reported,…

As previously reported, Deutsche Bank analyst Emmanuel Papadakis downgraded Roche (RHHBY) to Sell from Hold with a price target of CHF 265, down from CHF 300. In the research note, which was an EU Pharmaceuticals sector note that looked ahead to FY23, the analyst opined that Novo Nordisk (NVO) and Roche would both "break out of decade-long P/E multiple trading ranges (in opposite directions)." Papadakis sees Novo Nordisk remaining resilient short-term, but sees pressure looming in mid-FY23, but for Roche he believes the challenges will come sooner, as he has "little confidence in sufficiently strong TIGIT OS data," and sees "few catalysts beyond" and believes the consensus "remains optimistic on erosion curves for Actemra/Perjeta from 2024/25."

ShowHide Related Items >><<
RHHBY Roche
$39.91 /

+0.48 (+1.22%)

NVO Novo Nordisk
$140.55 /

+1.6 (+1.15%)

RHHBY Roche
$39.91 /

+0.48 (+1.22%)

01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/05/23 Jefferies
Roche downgraded on 'tougher 2023 catalyst path' at Jefferies
01/04/23 Jefferies
Roche downgraded to Hold from Buy at Jefferies
NVO Novo Nordisk
$140.55 /

+1.6 (+1.15%)

01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
RHHBY Roche
$39.91 /

+0.48 (+1.22%)

NVO Novo Nordisk
$140.55 /

+1.6 (+1.15%)

RHHBY Roche
$39.91 /

+0.48 (+1.22%)

NVO Novo Nordisk
$140.55 /

+1.6 (+1.15%)

RHHBY Roche
$39.91 /

+0.48 (+1.22%)

NVO Novo Nordisk
$140.55 /

+1.6 (+1.15%)

Hot Stocks
Novo Nordisk announces FDA approval of label update for Rybelsus » 07:24
01/13/23
01/13
07:24
01/13/23
07:24
NVO

Novo Nordisk

$133.62 /

+1.02 (+0.77%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration has approved a label update for Rybelsus tablets 7 mg or 14 mg, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment, Novo Nordisk announced "This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes. Initially approved by the FDA in 2019, Rybelsus is the first and only GLP-1 analog in pill form and is indicated, along with diet and exercise, to improve glycemic control for adults with type 2 diabetes," the company said.

ShowHide Related Items >><<
NVO Novo Nordisk
$133.62 /

+1.02 (+0.77%)

NVO Novo Nordisk
$133.62 /

+1.02 (+0.77%)

01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
NVO Novo Nordisk
$133.62 /

+1.02 (+0.77%)

NVO Novo Nordisk
$133.62 /

+1.02 (+0.77%)

NVO Novo Nordisk
$133.62 /

+1.02 (+0.77%)

Hot Stocks
California AG files suit against drugmakers, PBMs over insulin prices » 13:57
01/12/23
01/12
13:57
01/12/23
13:57
LLY

Eli Lilly

$358.90 /

-1.5 (-0.42%)

, SNY

Sanofi

$49.25 /

+0.52 (+1.07%)

, NVO

Novo Nordisk

$133.44 /

+0.84 (+0.63%)

, CVS

CVS Health

$89.23 /

-0.52 (-0.58%)

, CI

Cigna

$310.31 /

+1.18 (+0.38%)

, UNH

UnitedHealth

$495.80 /

+2.84 (+0.58%)

California Attorney…

California Attorney General Rob Bonta announced in a press conference that his office is filing a lawsuit against Eli Lilly (LLY), Novo Nordisk (NVO) and Sanofi (SNY) over insulin prices in the state. The suit also claims pharmacy benefit managers, or PBMs, CVS Caremark (CVS), Express Scripts (CI), and OptumRx (UNH) "have leveraged their market power to overcharge patients," according to Bonta. Reference Link

ShowHide Related Items >><<
UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

SNY Sanofi
$49.25 /

+0.52 (+1.07%)

NVO Novo Nordisk
$133.44 /

+0.84 (+0.63%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

CVS CVS Health
$89.23 /

-0.52 (-0.58%)

CI Cigna
$310.31 /

+1.18 (+0.38%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/03/23 Barclays
Eli Lilly price target raised to $400 from $395 at Barclays
12/23/22 Raymond James
ProQR Therapeutics price target raised to $5 from $2 at Raymond James
12/22/22 JMP Securities
ProQR Therapeutics shares remain 'fairly valued,' says JMP Securities
SNY Sanofi
$49.25 /

+0.52 (+1.07%)

12/21/22 Barclays
Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
12/16/22 Goldman Sachs
Sanofi reinstated with a Buy at Goldman Sachs
12/15/22 Guggenheim
Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
12/14/22 UBS
Sanofi price target raised to EUR 97 from EUR 92 at UBS
NVO Novo Nordisk
$133.44 /

+0.84 (+0.63%)

01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
CVS CVS Health
$89.23 /

-0.52 (-0.58%)

01/12/23 Piper Sandler
Oak Street could be worth over $49 per share in buyout, says Piper Sandler
01/12/23 Raymond James
Raymond James upgrades Oak Street on potential takeout by CVS
01/10/23 Stifel
Oak Street Health, CVS deal would make sense for both companies, says Stifel
01/10/23 Piper Sandler
Takeout report adds 'intrigue' to Oak Street story, says Piper Sandler
CI Cigna
$310.31 /

+1.18 (+0.38%)

01/03/23 Wells Fargo
Wells Fargo downgrades Cigna to Equal Weight, lowers price target to $355
01/03/23 Wells Fargo
Cigna downgraded to Equal Weight from Overweight at Wells Fargo
11/23/22 Morgan Stanley
Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley
11/23/22 Morgan Stanley
Cigna assumed with an Overweight at Morgan Stanley
UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

12/12/22 Wells Fargo
Wells Fargo downgrades Nevro to Equal Weight, lowers price target to $43
12/07/22 Credit Suisse
UnitedHealth price target raised to $610 from $590 at Credit Suisse
12/01/22 Craig-Hallum
Craig-Hallum upgrades eHealth to Buy on 'clear signs of life'
11/23/22 Morgan Stanley
UnitedHealth assumed with an Overweight at Morgan Stanley
UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

SNY Sanofi
$49.25 /

+0.52 (+1.07%)

NVO Novo Nordisk
$133.44 /

+0.84 (+0.63%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

CVS CVS Health
$89.23 /

-0.52 (-0.58%)

CI Cigna
$310.31 /

+1.18 (+0.38%)

UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

SNY Sanofi
$49.25 /

+0.52 (+1.07%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

CVS CVS Health
$89.23 /

-0.52 (-0.58%)

CI Cigna
$310.31 /

+1.18 (+0.38%)

UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

SNY Sanofi
$49.25 /

+0.52 (+1.07%)

NVO Novo Nordisk
$133.44 /

+0.84 (+0.63%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

CVS CVS Health
$89.23 /

-0.52 (-0.58%)

CI Cigna
$310.31 /

+1.18 (+0.38%)

UNH UnitedHealth
$495.80 /

+2.84 (+0.58%)

SNY Sanofi
$49.25 /

+0.52 (+1.07%)

LLY Eli Lilly
$358.90 /

-1.5 (-0.42%)

CVS CVS Health
$89.23 /

-0.52 (-0.58%)

Recommendations
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan » 15:17
01/03/23
01/03
15:17
01/03/23
15:17
NVO

Novo Nordisk

$136.71 /

+1.39 (+1.03%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Novo Nordisk to DKK 1,100 from DKK 925 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NVO Novo Nordisk
$136.71 /

+1.39 (+1.03%)

NVO Novo Nordisk
$136.71 /

+1.39 (+1.03%)

01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
NVO Novo Nordisk
$136.71 /

+1.39 (+1.03%)

NVO Novo Nordisk
$136.71 /

+1.39 (+1.03%)

NVO Novo Nordisk
$136.71 /

+1.39 (+1.03%)

Recommendations
Novo Nordisk added to Analyst Focus List at JPMorgan » 05:51
01/03/23
01/03
05:51
01/03/23
05:51
NVO

Novo Nordisk

$135.33 /

+0.155 (+0.11%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Novo Nordisk to DKK 1,100 from DKK 925 and keeps an Overweight rating on the shares. The anlayst also added the shares to the firm's Analyst Focus List. He continues to see a "bifurcation" in European pharma company outlooks in 2023, both in terms of pipeline readouts and longer-term where "genericisations again need to be navigated." As such, he would avoid companies like GSK and Roche, seeing downside to 2023 consensus estimates and "potentially challenged" 2025-2030 outlooks. Vosser continues to favor companies "which have sustainably higher growth" and "far more" pipeline data points, new launches to drive estimate upgrades.

ShowHide Related Items >><<
NVO Novo Nordisk
$135.33 /

+0.155 (+0.11%)

NVO Novo Nordisk
$135.33 /

+0.155 (+0.11%)

12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
NVO Novo Nordisk
$135.33 /

+0.155 (+0.11%)

NVO Novo Nordisk
$135.33 /

+0.155 (+0.11%)

NVO Novo Nordisk
$135.33 /

+0.155 (+0.11%)

Over a month ago
Recommendations
Novo Nordisk price target raised to $145 from $130 at Cowen » 07:38
12/12/22
12/12
07:38
12/12/22
07:38
NVO

Novo Nordisk

$128.94 /

+1.115 (+0.87%)

Cowen analyst Michael…

Cowen analyst Michael Nedelcovych raised the firm's price target on Novo Nordisk to $145 from $130 and keeps an Outperform rating on the shares. The analyst said Novo could be a top performing drug stock in 2023 as uncertainties around the trajectory of its GLP-1 franchises may be set to fall away.

ShowHide Related Items >><<
NVO Novo Nordisk
$128.94 /

+1.115 (+0.87%)

NVO Novo Nordisk
$128.94 /

+1.115 (+0.87%)

11/28/22 Berenberg
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg
11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
NVO Novo Nordisk
$128.94 /

+1.115 (+0.87%)

NVO Novo Nordisk
$128.94 /

+1.115 (+0.87%)

NVO Novo Nordisk
$128.94 /

+1.115 (+0.87%)

Recommendations
Novo Nordisk price target raised to DKK 810 from DKK 780 at Berenberg » 13:13
11/28/22
11/28
13:13
11/28/22
13:13
NVO

Novo Nordisk

$120.25 /

+0.85 (+0.71%)

Berenberg analyst Luisa…

Berenberg analyst Luisa Hector raised the firm's price target on Novo Nordisk to DKK 810 from DKK 780 and keeps a Hold rating on the shares.

ShowHide Related Items >><<
NVO Novo Nordisk
$120.25 /

+0.85 (+0.71%)

NVO Novo Nordisk
$120.25 /

+0.85 (+0.71%)

11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
NVO Novo Nordisk
$120.25 /

+0.85 (+0.71%)

NVO Novo Nordisk
$120.25 /

+0.85 (+0.71%)

NVO Novo Nordisk
$120.25 /

+0.85 (+0.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.